Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Accounts Payables (2022 - 2025)

Atara Biotherapeutics' Accounts Payables history spans 4 years, with the latest figure at $127000.0 for Q4 2025.

  • For Q4 2025, Accounts Payables fell 97.09% year-over-year to $127000.0; the TTM value through Dec 2025 reached $127000.0, down 97.09%, while the annual FY2025 figure was $127000.0, 97.09% down from the prior year.
  • Accounts Payables reached $127000.0 in Q4 2025 per ATRA's latest filing, down from $318000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $12.8 million in Q2 2022 to a low of $127000.0 in Q4 2025.
  • Average Accounts Payables over 4 years is $5.0 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: grew 26.95% in 2024, then tumbled 97.09% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $6.9 million in 2022, then tumbled by 46.38% to $3.7 million in 2023, then rose by 18.54% to $4.4 million in 2024, then crashed by 97.09% to $127000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Accounts Payables are $127000.0 (Q4 2025), $318000.0 (Q3 2025), and $1.8 million (Q2 2025).